Obviousness

US patent 12031894B2, titled "Analytical ultracentrifugation for characterization of recombinant viral particles," describes methods for characterizing preparations of recombinant viral particles using analytical ultracentrifugation (AUC) under boundary sedimentation velocity conditions. The invention focuses on monitoring sedimentation, plotting the differential sedimentation coefficient distribution value (C(s)) versus the sedimentation coefficient in Svedberg units (S), and integrating peak areas to determine the relative concentration of different species of recombinant viral particles. These species can include full recombinant viral particles with intact genomes, empty capsids, and variant viral particles containing fragmented genomes, aggregates, or DNA impurities. The methods are stated to be applicable to recombinant adeno-associated viral (rAAV) particles, recombinant adenoviral (rAd) particles, recombinant lentiviral particles, and recombinant herpes simplex viral (rHSV) particles.

The patent aims to provide a generic assay for characterizing recombinant viral preparations, independent of the viral genome sequence or capsid serotype, addressing a perceived need for improved analytical methods beyond traditional techniques like Southern blot and immunoassays.

Obviousness Analysis under 35 U.S.C. § 103

A person having ordinary skill in the art (PHOSITA) in 2015, the priority date of US12031894B2, would have found the claimed methods obvious in light of existing prior art, particularly the disclosure of analytical ultracentrifugation for characterizing adenovirus preparations and the common knowledge regarding the versatility of AUC.

Prior Art References:

1. Berkowitz, S A & Philo J S, (2007) Anal. Biochem., 362:16-37: This publication is explicitly cited in US12031894B2 and teaches the "Use of analytical ultracentrifugation to characterize adenovirus preparations".
2. Schuck (2000) Biophys. J., 78:1606-19: This reference describes the SEDFIT algorithm, which utilizes Lamm equation solutions for analyzing hydrodynamic data such as sedimentation velocity. The present patent acknowledges that C(S) values are determined by algorithms comprising Lamm equation solutions, specifically mentioning SEDFIT.
3. Cole et al. (2008) Methods Cell Biol., 84:143-79: This publication provides general methods for optically detecting a sedimenting boundary and measuring its rate of movement or migration in AUC.
4. Furst (1997) Eur. Biophys. J. 35:307-10: This reference describes the use of Rayleigh interference optics with AUC.
5. General Knowledge in the Art regarding Gene Therapy Vectors and AUC Principles: The patent itself cites numerous references illustrating the widespread use and understanding of rAAV, rAd, lentivirus, and rHSV in gene therapy applications, as well as various production and purification methods for these vectors (e.g., Conway, J E et al., (1997) J. Virology 71(11):8780-8789; Danthinne, X. and Imperiale, M. J. (2000) Gene Ther. 7:1707-14; Tatsis, N. and Ertl, H. C. (2004) Mol. Ther. 10:616-29; Thorne et al. (2009) Hum. Gene Ther., 20:707-14). The fundamental principles of AUC, including its ability to resolve different particle species based on molecular weight and shape, were well-established.

Combinations and Rationale for Obviousness:

The primary claims of US12031894B2 revolve around applying established AUC techniques to characterize various recombinant viral particles. This would have been obvious to a PHOSITA by combining the specific teaching of Berkowitz & Philo (2007) with the general knowledge in the field of virology and biophysical characterization.

Combination 1: Berkowitz & Philo (2007) + General knowledge in the art (including Schuck (2000), Cole et al. (2008), Furst (1997), and knowledge of various viral vectors)

1. Disclosure by Berkowitz & Philo (2007): This reference clearly teaches the application of AUC for the characterization of adenovirus preparations. Characterizing viral preparations using AUC inherently involves monitoring sedimentation, plotting C(s) versus S (or equivalent distributions), and identifying different particle species based on their sedimentation coefficients, such as empty versus full capsids, aggregates, or fragments. These are standard analytical outputs of AUC sedimentation velocity experiments.
2. Motivation to Combine/Apply to Other Viral Particles:
   • Known Versatility of AUC: As explicitly stated in US12031894B2, "AUC analysis has been well characterized over many decades and is highly versatile. Because AUC analysis relies upon first-principle hydrodynamic and thermodynamic information, AUC may be applied to determine the biophysical properties of many types of particles across a wide range of particle concentrations and sizes". A PHOSITA would recognize AUC as a broadly applicable technique for macromolecule characterization.
   • Common Need for Characterization: The background of US12031894B2 highlights the ongoing need for robust analytical methods to monitor the quality of recombinant viral vectors (including rAAV, lentivirus, and rHSV) for gene therapy applications, particularly regarding homogeneity, purity, and consistency of manufacturing. Existing methods like Southern blots and immunoassays were recognized as having limitations. Faced with the problem of needing a generic and comprehensive characterization method for various viral vectors, a PHOSITA would naturally consider applying a powerful biophysical technique already shown useful for one type of viral vector (adenovirus, per Berkowitz & Philo) to other similar viral systems.
   • Predictable Results based on Viral Sizes: US12031894B2 itself provides a strong rationale for extending the method: "Without wishing to be bound to theory, a range of AUC settings that allows the analysis of both AAV and adenovirus particles should enable the analysis of other viral particles including lentivirus and HSV since the size of HSV and lentiviral particles is between that of AAV and adenovirus particles". This statement effectively describes the expectation of a PHOSITA – that a method successful for adenovirus could be adapted to other viral particles with known size relationships. The adjustment of AUC parameters (e.g., rotor speed, temperature, monitoring intervals) for different sample types is a routine optimization task for a PHOSITA operating AUC instrumentation.
3. Obvious Steps for Applying AUC:
   • Monitoring sedimentation, plotting C(s) vs S, and integrating peaks: These are standard operational procedures and data analysis techniques taught in the art of AUC. Schuck (2000) details the Lamm equation solutions and the SEDFIT algorithm for analyzing sedimentation velocity data to derive C(s) distributions. Cole et al. (2008) and Furst (1997) describe various optical detection methods (absorbance and interference) commonly used in AUC.
   • Identifying different species (empty, full, variant genomes): The ability of AUC to distinguish particles based on mass and shape means that different viral species (e.g., empty capsids lacking a genome versus full capsids containing a genome, or capsids with different genome sizes/aggregates) would inherently exhibit distinct sedimentation coefficients, leading to separable peaks in the C(s) distribution. Interpreting these peaks as different viral species (full, empty, variant) would be a straightforward and expected outcome for a PHOSITA applying AUC to viral preparations.
   • Assessing genome integrity via standard curves: The concept of establishing a correlation between a biophysical parameter (like sedimentation coefficient) and a molecular property (like genome size) using a standard curve is a routine analytical practice, especially once it is observed that different genome sizes yield different S-values (as shown in Figure 8 of US12031894B2 for AAV).
   • Monitoring purification and heterogeneity: The use of AUC as a quality control tool to monitor changes in particle populations (e.g., reduction of empty capsids or variant genomes, increase in full capsids) during purification steps is a logical extension of its analytical capabilities and a common application of analytical techniques in bioprocessing.

Therefore, the combination of Berkowitz & Philo (2007), which demonstrates the utility of AUC for adenovirus characterization, with the general knowledge in the field regarding AUC's versatility, the existence and properties of various recombinant viral vectors, and the ongoing need for their characterization, would have rendered the claimed methods obvious to a PHOSITA. The patent's own justification for extending AUC to AAV, lentivirus, and HSV further underscores this obviousness.